Breye Therapeutics

Breye Therapeutics is a Danish biotech advancing oral therapies for retinal diseases like diabetic retinopathy and age-related macular degeneration. Its lead asset, danegaptide, has reported positive Phase 1b data, and the company is also developing a platform of oral P2X7 receptor antagonists. With a seasoned leadership team and a focus on significant unmet needs in ophthalmology, Breye is positioning itself to address a large market with convenient oral alternatives to current invasive treatments.

Platform for developing orally bioavailable small molecules, including a novel compound (danegaptide) and P2X7 receptor antagonists targeting inflammation and neuroprotection in the retina.

Breye competes in a crowded ophthalmology space dominated by anti-VEGF injectables from Roche/Genentech and Regeneron. It faces competition from other companies developing longer-acting injections, implants, gene therapies, and oral therapies. Its key differentiator is the convenience of an oral pill, but it must prove comparable efficacy to entrenched standards of care.